Dr. Hendifar Discusses a 92-Gene Assay of NETs

Andrew E. Hendifar, MD
Published: Monday, Nov 27, 2017



Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).

This 92-gene assay is a molecular classification of NETs, says Hendifar. The original validation set looked at over 2,000 tumors and sequenced over 22,000 genes to create this reference set of 92 genes.

Hendifar says this assay was done in an effort to better understand and characterize NETs that are diagnosed as an unknown primary.


Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).

This 92-gene assay is a molecular classification of NETs, says Hendifar. The original validation set looked at over 2,000 tumors and sequenced over 22,000 genes to create this reference set of 92 genes.

Hendifar says this assay was done in an effort to better understand and characterize NETs that are diagnosed as an unknown primary.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Cancer Summaries and Commentaries™: Update from San Diego - Advances in the Treatment of Multiple MyelomaJan 31, 20181.5
Publication Bottom Border
Border Publication
x